Giant pituitary adenomas (GPAs), which are defined as tumors with a maximum diameter larger than 40 mm, account for 5-14% of adenomas that are treated surgically (1,2). Surgery for patients with a GPA is challenging due to the enormous tumor size, irregular extension, and invasiveness. Gross total resection (GTR) is achieved in less than 50% of GPAs, with a reported 10% to 20% complication rate (1,3,4). Surgery remains the main treatment option for GPA, excluding most prolactinomas. Recently, with advances in endoscopic surgical techniques,